Proteinuria: abate or applaud abatacept in proteinuric kidney disease?

Jochen Reiser, Nada Alachkar

Research output: Contribution to journalReview article


T-lymphocyte activation antigen CD80 is a B-cell costimulator and podocyte injury marker originally described in lupus nephritis; CD80 blockade with abatacept disappointed in a lupus nephritis trial. A study now suggests abatacept efficacy in focal and segmental glomerulosclerosis. Small patient numbers and concurrent treatment regimens call for more definitive studies regarding this therapeutic strategy.

Original languageEnglish (US)
Pages (from-to)128-130
Number of pages3
JournalNature reviews. Nephrology
Issue number3
StatePublished - Mar 2014


ASJC Scopus subject areas

  • Nephrology

Cite this